|
1
|
Cheng JQ, Jiang X, Fraser M, Li M, Dan HC,
Sun M and Tsang BK: Role of X-linked inhibitor of apoptosis protein
in chemoresistance in ovarian cancer: Possible involvement of the
phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat.
5:131–146. 2002. View Article : Google Scholar
|
|
2
|
Russo A, Czarnecki AA, Dean M, Modi DA,
Lantvit DD, Hardy L, Baligod S, Davis DA, Wei JJ and Burdette JE:
PTEN loss in the fallopian tube induces hyperplasia and ovarian
tumor formation. Oncogene. 37:1976–1990. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Zyl B, Tang D and Bowden NA:
Biomarkers of platinum resistance in ovarian cancer: What can we
use to improve treatment. Endocr Relat Cancer. 25:R303–R318. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ricciardelli C, Lokman NA, Ween MP and
Oehler MK: Women in cancer thematic review: Ovarian
cancer-peritoneal cell interactions promote extracellular matrix
processing. Endocr Relat Cancer. 23:T155–T168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li KY, Zhang J, Jiang LC, Zhang B, Xia CP,
Xu K, Chen HY, Yang QZ, Liu SW and Zhu H: Knockdown of USP39 by
lentivirus-mediated RNA interference suppresses the growth of oral
squamous cell carcinoma. Cancer Biomark. 16:137–144. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao Y, Zhang B, Lei Y, Sun J, Zhang Y,
Yang S and Zhang X: Knockdown of USP39 induces cell cycle arrest
and apoptosis in melanoma. Tumour Biol. 37:13167–13176. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ríos Y, Melmed S, Lin S and Liu NA:
Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and
pituitary lineage expansion. PLoS Genet. 7:e10012712011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fraile JM, Manchado E, Lujambio A, Quesada
V, Campos-Iglesias D, Webb TR, Lowe SW, López-Otín C and Freije JM:
USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer.
J Biol Chem. 292:4164–4175. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
An Y, Yang S, Guo K, Ma B and Wang Y:
Reduced USP39 expression inhibits malignant proliferation of
medullary thyroid carcinoma in vitro. World J Surg Oncol.
13:2552015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang Y, Pan XW, Li L, Chen L, Liu X, Lu
JL, Zhu XM, Huang H, Yang QW, Ye JQ, et al: Overexpression of USP39
predicts poor prognosis and promotes tumorigenesis of prostate
cancer via promoting EGFR mRNA maturation and transcription
elongation. Oncotarget. 7:22016–22030. 2016.PubMed/NCBI
|
|
11
|
Wang H, Ji X, Liu X, Yao R, Chi J, Liu S,
Wang Y, Cao W and Zhou Q: Lentivirus-mediated inhibition of USP39
suppresses the growth of breast cancer cells in vitro. Oncol Rep.
30:2871–2877. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Kong Y, Zhou Z, Chen H, Wang Z,
Hsieh YC, Zhao D, Zhi X, Huang J, Zhang J, et al: The HECTD3 E3
ubiquitin ligase facilitates cancer cell survival by promoting
K63-linked polyu-biquitination of caspase-8. Cell Death Dis.
4:e9352013. View Article : Google Scholar
|
|
13
|
Shu T, Li Y, Wu X, Li B and Liu Z:
Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian
cancer cells sensitive to platinum treatment. Cancer Lett.
411:65–73. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Δ Δ C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
15
|
Wu X, Luo Q, Zhao P, Chang W, Wang Y, Shu
T, Ding F, Li B and Liu Z: MGMT-activated DUB3 stabilizes MCL1 and
drives chemoresistance in ovarian cancer. Proc Natl Acad Sci USA.
116:2961–2966. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ueno M, Shiomi T, Mochizuki S, Chijiiwa M,
Shimoda M, Kanai Y, Kataoka F, Hirasawa A, Susumu N, Aoki D, et al:
ADAM9 is over-expressed in human ovarian clear cell carcinomas and
suppresses cisplatin-induced cell death. Cancer Sci. 109:471–482.
2018. View Article : Google Scholar :
|
|
17
|
Xu Y, Miao C, Jin C, Qiu C, Li Y, Sun X,
Gao M, Lu N and Kong B: SUSD2 promotes cancer metastasis and
confers cisplatin resistance in high grade serous ovarian cancer.
Exp Cell Res. 363:160–170. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Longoria TC and Tewari KS: Pharmacokinetic
drug evaluation of niraparib for the treatment of ovarian cancer.
Expert Opin Drug Metab Toxicol. 14:543–550. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ricciardelli C, Lokman NA, Sabit I,
Gunasegaran K, Bonner WM, Pyragius CE, Macpherson AM and Oehler MK:
Novel ex vivo ovarian cancer tissue explant assay for prediction of
chemosensitivity and response to novel therapeutics. Cancer Lett.
421:51–58. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wei W, Giulia F, Luffer S, Kumar R, Wu B,
Tavallai M, Bekele RT and Birrer MJ: How can molecular
abnormalities influence our clinical approach. Ann Oncol.
28:viii16–viii24. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang P, Zhang P, Shi B, Zhou M, Jiang H,
Zhang H, Pan X, Gao H, Sun H and Li Z: Galectin-1 overexpression
promotes progression and chemoresistance to cisplatin in epithelial
ovarian cancer. Cell Death Dis. 5:e9912014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Birkbak NJ, Li Y, Pathania S,
Greene-Colozzi A, Dreze M, Bowman-Colin C, Sztupinszki Z,
Krzystanek M, Diossy M, Tung N, et al: Overexpression of BLM
promotes DNA damage and increased sensitivity to platinum salts in
triple-negative breast and serous ovarian cancers. Ann Oncol.
29:903–909. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Chen D, Qian H, Tsai YS, Shao S,
Liu Q, Dominguez D and Wang Z: The splicing factor RBM4 controls
apoptosis, proliferation, and migration to suppress tumor
progression. Cancer Cell. 26:374–389. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
No authors listed. RBM4-regulated
alternative splicing suppresses tumorigenesis. Cancer Discov.
4:12532014. View Article : Google Scholar
|
|
25
|
Chen L, Luo C, Shen L, Liu Y, Wang Q,
Zhang C, Guo R, Zhang Y, Xie Z, Wei N, et al: SRSF1 Prevents DNA
Damage and Promotes Tumorigenesis through Regulation of DBF4B
Pre-mRNA Splicing. Cell Rep. 21:3406–3413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Anczuków O, Akerman M, Cléry A, Wu J, Shen
C, Shirole NH, Raimer A, Sun S, Jensen MA, Hua Y, et al:
SRSF1-regulated alternative splicing in breast cancer. Mol Cell.
60:105–117. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gan Z, Han K, Lin S, Hu H, Shen Z and Min
D: Knockdown of ubiquitin-specific peptidase 39 inhibited the
growth of osteo-sarcoma cells and induced apoptosis in vitro. Biol
Res. 50:152017. View Article : Google Scholar
|
|
28
|
Pan Z, Pan H, Zhang J, Yang Y, Liu H, Yang
Y, Huang G, Ni J, Huang J and Zhou W: Lentivirus mediated silencing
of ubiquitin specific peptidase 39 inhibits cell proliferation of
human hepato-cellular carcinoma cells in vitro. Biol Res.
48:182015. View Article : Google Scholar
|
|
29
|
Tuan Anh HL, Tran PT, Thao DT, Trang DT,
Dang NH, Van Cuong P, Kiem PV, Minh CV and Lee JH:
Degalactotigonin, a steroidal glycoside from solanum nigrum,
induces apoptosis and cell cycle arrest via inhibiting the EGFR
signaling pathways in pancreatic cancer cells. BioMed Res Int.
2018:31209722018. View Article : Google Scholar
|
